← back to search

Ruggero De Maria

Università Cattolica del Sacro Cuore · IT
🔎 Find collaborators in Oncology · Pulmonary and Respiratory Medicine · tumor microenvironment CAR-T →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pulmonary and Respiratory Medicine · tumor microenvironment CAR-T
Research interest
Research interests include Cancer Cells and Metastasis, Lung Cancer Treatments and Mutations, Cell death mechanisms and regulation, and Cancer Immunotherapy and Biomarkers.
h-index
86
citations
40,474
works
474
NIH funding
primary concept
Medicine
email

Recent publications

Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody.
2026cited by 0position: contributordoi
An IGF2-anchored oncofetal state and relapse-associated transcriptomic module define systemic progression risk in early-onset colorectal cancer
2026cited by 0position: contributordoi
A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium.
2025cited by 0position: contributordoi
Advancements in 3D In Vitro Models for Colorectal Cancer.
2024cited by 13position: contributordoi
UNCAN.eu: Toward a European Federated Cancer Research Data Hub
Cancer Discovery 2024cited by 5position: middledoi
The 1+Million Genomes Minimal Dataset for Cancer.
2024cited by 5position: contributordoi
UNCAN.eu: Toward a European Federated Cancer Research Data Hub.
2024cited by 4position: contributordoi
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.
2024cited by 1position: contributordoi
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
2024cited by 0position: contributordoi
Supplementary Figure S5 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Table S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S22 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S1 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Table S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S21 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S16 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S20 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S14 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Table S2 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Table S5 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S10 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S4 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S15 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S11 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S17 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S12 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Data from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S19 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi
Supplementary Figure S13 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2021–2026)Marcello Maugeri‐Saccà · National Cancer Institute8 papers (2012–2021) · 5 papers (2012–2023)Gennaro Ciliberto · Istituti Fisioterapici Ospitalieri4 papers (2018–2021) · 4 papers (2012–2018)Maddalena Barba · University of Birmingham4 papers (2015–2016)Giovanni Muto · Università Campus Bio-Medico4 papers (2012–2018)Francesca Sperati · Istituti Fisioterapici Ospitalieri4 papers (2014–2024) · 4 papers (2012–2023)Daniele Santini · Azienda Ospedaliera Sant'Andrea4 papers (2015–2016) · 4 papers (2015–2016)Michele Signore · 4 papers (2019–2026)Laura Pizzuti · National Cancer Institute4 papers (2015–2016)Patrizia Vici · National Cancer Institute4 papers (2015–2016) · 4 papers (2012–2017) · 4 papers (2014–2016)Domenico Sergi · University of Ferrara4 papers (2015–2016) · 4 papers (2012–2018)Paolo Marchetti · Sapienza University of Rome3 papers (2016–2019) · 3 papers (2012–2018)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pulmonary and Respiratory Medicine · tumor microenvironment CAR-T →